Shin Nippon Biomedical Laboratories, Ltd. (FRA:YB3)

FRA:YB3 Balance Sheet

Financials in millions JPY. Fiscal year is April - March.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2025	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Cash & Equivalents	11,557	12,032	10,274	10,533	6,628	7,230
Short-Term Investments	-	-	336	-	368	55
Cash & Short-Term Investments	11,557	12,032	10,610	10,533	6,996	7,285
Cash Growth	3.14%	13.40%	0.73%	50.56%	-3.97%	38.79%
Receivables	5,914	6,513	5,722	4,695	3,499	2,952
Inventory	12,734	12,618	12,373	7,329	4,359	4,071
Other Current Assets	1,179	1,776	2,132	1,342	1,280	472
Total Current Assets	31,384	32,939	30,837	23,899	16,134	14,780
Property, Plant & Equipment	35,380	34,832	26,357	18,879	13,155	12,897
Long-Term Investments	22,180	20,469	15,926	12,404	8,645	8,522
Goodwill	1,777	1,884	1,934	1,438	-	-
Other Intangible Assets	256	219	225	261	212	213
Long-Term Deferred Tax Assets	-	2,036	989	325	1,129	521
Other Long-Term Assets	1	2	2	2	1	2
Total Assets	90,978	92,416	76,302	57,242	39,312	36,972
Accounts Payable	500	460	460	419	64	95
Short-Term Debt	14,229	11,777	7,826	8,923	2,942	3,486
Current Income Taxes Payable	150	2,217	1,701	603	743	683
Other Current Liabilities	13,583	14,802	13,580	11,066	9,624	7,651
Total Current Liabilities	28,462	29,256	23,567	21,011	13,373	11,915
Long-Term Debt	23,425	22,271	18,147	9,480	5,809	8,669
Long-Term Leases	469	425	212	357	385	529
Long-Term Deferred Tax Liabilities	-	235	84	-	-	-
Other Long-Term Liabilities	397	145	133	36	22	20
Total Liabilities	52,753	52,332	42,143	30,884	19,589	21,133
Common Stock	9,679	9,679	9,679	9,679	9,679	9,679
Additional Paid-In Capital	2,398	2,358	2,358	2,306	2,306	2,306
Retained Earnings	19,899	20,087	17,215	13,766	10,196	3,854
Comprehensive Income & Other	5,897	7,898	4,861	460	-2,620	-104
Total Common Equity	37,873	40,022	34,113	26,211	19,561	15,735
Minority Interest	352	62	46	147	162	104
Shareholders' Equity	38,225	40,084	34,159	26,358	19,723	15,839
Total Liabilities & Equity	90,978	92,416	76,302	57,242	39,312	36,972
Total Debt	38,123	34,473	26,185	18,760	9,136	12,684
Net Cash (Debt)	-26,566	-22,441	-15,575	-8,227	-2,140	-5,399
Net Cash Per Share	-638.13	-539.05	-374.12	-197.62	-51.40	-129.68
Filing Date Shares Outstanding	41.63	41.63	41.63	41.63	41.63	41.63
Total Common Shares Outstanding	41.63	41.63	41.63	41.63	41.63	41.63
Working Capital	2,922	3,683	7,270	2,888	2,761	2,865
Book Value Per Share	909.71	961.33	819.40	629.59	469.85	377.95
Tangible Book Value	35,840	37,919	31,954	24,512	19,349	15,522
Tangible Book Value Per Share	860.88	910.82	767.54	588.78	464.76	372.84
Order Backlog	-	35,690	34,404	29,249	19,724	13,447

Source: S&P Global Market Intelligence. Standard template. Financial Sources.